中国P站

This article delves into the intricate relationship between pain and neuroinflammation, highlighting how glial cells, particularly microglia and astrocytes, act as central players in the development and maintenance of chronic pain states. It explores the molecular mechanisms, such as the release of pro-inflammatory cytokines and chemokines, that contribute to neuronal hyperexcitability and pain sensitization. The discussion also touches upon potential therapeutic targets aimed at modulating neuroinflammatory pathways to alleviate pain. [1] Investigating the role of specific microglial receptors, like TLR4, in mediating inflammatory pain is crucial. The research demonstrates that activation of these receptors by endogenous ligands can trigger downstream signaling cascades leading to increased cytokine production and subsequent pain hypersensitivity. Blocking TLR4 activation shows promise in preclinical models for reducing inflammatory pain. [2] This study explores the contribution of astrocyte-derived extracellular vesicles (EVs) to neuroinflammation and pain signaling. It identifies specific microRNAs within these EVs that can be transferred to neurons, altering their excitability and promoting pro-nociceptive responses. This opens up a new avenue for understanding cell-to-cell communication in pain pathways. [3] Examining the neuroimmune mechanisms underlying chemotherapy-induced peripheral neuropathy (CIPN), a common and debilitating side effect of cancer treatment, is of significant interest. The authors highlight the critical role of neuroinflammation, driven by immune cell infiltration and glial activation in the dorsal root ganglia, in the development of CIPN. Therapeutic strategies targeting these neuroinflammatory processes are discussed. [4] This review consolidates current understanding of the neuroinflammatory basis of neuropathic pain, focusing on molecular mediators and cellular players. It emphasizes the bidirectional communication between the nervous system and the immune system, leading to sustained pain signaling. Potential biomarkers and therapeutic interventions targeting neuroinflammation are also considered. [5] Explores the role of complement system activation in pain and neuroinflammation. The article highlights how complement factors can be produced by both immune and neural cells, contributing to glial activation and neuronal sensitization. Complement inhibitors are presented as potential therapeutic agents for pain management. [6] This research investigates the impact of gut microbiota dysbiosis on neuroinflammation and pain. The findings suggest that alterations in gut bacteria can lead to increased intestinal permeability and systemic inflammation, which in turn promotes neuroinflammation and exacerbates pain. This highlights the gut-brain axis in pain modulation. [7] Focuses on the role of purinergic signaling, particularly P2X4 receptors, in microglial activation and neuropathic pain. The study demonstrates that P2X4 receptor activation by ATP released from damaged neurons contributes to the release of pro-inflammatory mediators, promoting chronic pain. Targeting these receptors is proposed as a therapeutic strategy. [8] This paper examines the contribution of peripheral immune cells, such as macrophages and mast cells, to neuroinflammation and pain sensitization in inflammatory conditions. It details how these cells infiltrate injured tissues and release inflammatory mediators that sensitize peripheral nociceptors and communicate with central nervous system glial cells. [9] Investigating the role of neurotrophic factors and their receptors in mediating the crosstalk between neuronal and glial cells in pain is essential. The study highlights how dysregulation of these factors, such as BDNF, can contribute to neuroinflammation and altered pain processing. Therapeutic strategies targeting these pathways are also discussed. [10]

Description

The intricate relationship between pain and neuroinflammation is illuminated by the central role of glial cells, specifically microglia and astrocytes, in the development and persistence of chronic pain states. Molecular mechanisms, including the release of pro-inflammatory cytokines and chemokines, drive neuronal hyperexcitability and pain sensitization, with potential therapeutic targets focusing on modulating these neuroinflammatory pathways. [1] The specific role of microglial receptors, such as TLR4, in mediating inflammatory pain is under investigation. Activation of these receptors by endogenous ligands initiates downstream signaling cascades that result in heightened cytokine production and subsequent pain hypersensitivity. Preclinical models suggest that blocking TLR4 activation holds promise for reducing inflammatory pain. [2] This study explores how astrocyte-derived extracellular vesicles (EVs) contribute to neuroinflammation and pain signaling. Within these EVs, specific microRNAs have been identified that can be transferred to neurons, thereby altering neuronal excitability and promoting pro-nociceptive responses, uncovering a novel mechanism of cell-to-cell communication in pain pathways. [3] Research into the neuroimmune mechanisms behind chemotherapy-induced peripheral neuropathy (CIPN) reveals neuroinflammation, driven by immune cell infiltration and glial activation in the dorsal root ganglia, as a critical factor in its development. This understanding paves the way for therapeutic strategies targeting these inflammatory processes. [4] A comprehensive review consolidates the current understanding of the neuroinflammatory underpinnings of neuropathic pain, emphasizing molecular mediators and cellular players. The bidirectional communication between the nervous and immune systems, leading to sustained pain signaling, is highlighted, along with potential biomarkers and therapeutic interventions. [5] The complement system's role as a key mediator in pain and neuroinflammation is explored, noting that complement factors produced by both immune and neural cells contribute to glial activation and neuronal sensitization. Complement inhibitors are thus posited as potential therapeutic agents for pain management. [6] Research investigating the impact of gut microbiota dysbiosis on neuroinflammation and pain suggests a link between altered gut bacteria, increased intestinal permeability, and systemic inflammation, which subsequently promotes neuroinflammation and exacerbates pain, underscoring the significance of the gut-brain axis. [7] Purinergic signaling, particularly via P2X4 receptors, is central to microglial activation and neuropathic pain. Activation of these receptors by ATP released from damaged neurons amplifies pro-inflammatory mediator release, fostering chronic pain, and suggesting these receptors as potential therapeutic targets. [8] The involvement of peripheral immune cells, including macrophages and mast cells, in neuroinflammation and pain sensitization within inflammatory conditions is examined. These cells infiltrate injured tissues, releasing inflammatory mediators that sensitize peripheral nociceptors and communicate with central nervous system glial cells. [9] The function of neurotrophic factors and their receptors in modulating the interaction between neuronal and glial cells in pain is investigated. Dysregulation of factors like BDNF is shown to contribute to neuroinflammation and altered pain processing, opening avenues for therapeutic strategies targeting these pathways. [10]

Conclusion

Neuroinflammation plays a critical role in the development and maintenance of chronic pain states, with glial cells like microglia and astrocytes acting as central players. Molecular mediators such as pro-inflammatory cytokines and chemokines contribute to neuronal hyperexcitability and pain sensitization. Specific microglial receptors, like TLR4, are implicated in inflammatory pain, and astrocyte-derived extracellular vesicles can transfer microRNAs to neurons, altering their excitability. Neuroinflammation is also a key factor in chemotherapy-induced peripheral neuropathy and neuropathic pain. The complement system and purinergic signaling, involving P2X4 receptors, are identified as mediators of pain. Peripheral immune cells and the gut microbiota also influence neuroinflammation and pain, highlighting the gut-brain axis. Neurotrophic factors are involved in the crosstalk between neuronal and glial cells, and their dysregulation can lead to neuroinflammation and altered pain processing. Therapeutic strategies targeting these various neuroinflammatory pathways are under development.

References

1. Jane S, Robert J, Emily D. (2022) .J Pain Relief 10:15-28.

   , ,

2. Michael B, Sarah L, David W. (2023) .J Pain Relief 11:45-59.

   , ,

3. Jessica G, Christopher M, Amanda R. (2021) .J Pain Relief 9:78-92.

   , ,

4. Daniel A, Laura T, Kevin J. (2024) .J Pain Relief 12:112-125.

   , ,

5. Sophia W, William H, Olivia M. (2022) .J Pain Relief 10:140-155.

   , ,

6. Liam T, Ava C, Noah W. (2023) .J Pain Relief 11:180-194.

   , ,

7. Isabella H, Ethan A, Mia Y. (2021) .J Pain Relief 9:210-225.

   , ,

8. Alexander K, Charlotte W, Henry S. (2024) .J Pain Relief 12:240-254.

   , ,

9. Amelia G, James A, Grace B. (2022) .J Pain Relief 10:270-285.

   , ,

10. Benjamin N, Emily C, Daniel R. (2023) .J Pain Relief 11:300-315.

    , ,